Effect of St John's Wort on imatinib mesylate pharmacokinetics
暂无分享,去创建一个
[1] R. Capdeville,et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects , 2004, Cancer Chemotherapy and Pharmacology.
[2] R. Day,et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. , 2004, British journal of clinical pharmacology.
[3] H. Kantarjian,et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.
[4] S. Krähenbühl,et al. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. , 2004, British journal of clinical pharmacology.
[5] B. Dörken,et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 , 2004, Cancer Chemotherapy and Pharmacology.
[6] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Ben-Am,et al. Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion , 2004, Journal of clinical pharmacology.
[8] M. Hebert,et al. Effects of St. John's Wort (Hypericum perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers , 2004, Journal of clinical pharmacology.
[9] Shiew-Mei Huang,et al. The interaction between St John's wort and an oral contraceptive , 2003, Clinical pharmacology and therapeutics.
[10] M. Egorin,et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] J. Brockmöller,et al. Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6β-hydroxycortisol in healthy volunteers , 2002, European Journal of Clinical Pharmacology.
[12] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[13] H. Yoshimoto,et al. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. , 2002, British journal of clinical pharmacology.
[14] J. Wood,et al. Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.
[15] Shiew-Mei Huang,et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity , 2001, Clinical pharmacology and therapeutics.
[16] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[17] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[18] J. Azuma,et al. Specific determination of urinary 6beta-hydroxycortisol and cortisol by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[19] S. Singletary,et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Moore,et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. D. Rodrigues,et al. Simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[22] A. Burstein,et al. St John's Wort: Effect on CYP3A4 activity , 2000 .
[23] J. Falloon,et al. Indinavir concentrations and St John's wort , 2000, The Lancet.
[24] K. Brøsen,et al. Rifampicin treatment greatly increases the apparent oral clearance of quinidine. , 1999, Pharmacology & toxicology.
[25] S. J. Kovacs,et al. Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction , 1999, Journal of clinical pharmacology.
[26] D. Jorkasky,et al. Urinary excretion of 6β‐hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations , 1998, Clinical pharmacology and therapeutics.
[27] S. Fosså,et al. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. , 1997, European journal of cancer.
[28] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.